Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes

Next Previous
X
Search
Trial Profile

A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors AMG Medical; Locemia Solutions

    • Most Recent Events

    • 22 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 07 Mar 2016 Planned End Date changed from 1 Nov 2015 to 1 Apr 2016 according to the ClinicalTrials.gov record
    • 10 Aug 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top